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ABSTRACT
Background. Liver transplantation (LT) has been per-
formed in a select group of patients presenting with
unresectable or primary sclerosing cholangitis (PSC)-as-
sociated perihilar cholangiocarcinoma (pCCA) in the Mayo
Clinic with a reported 5-year overall survival (OS) of 53%
on intention-to-treat analysis. The objective of this study
was to estimate eligibility for LT in a cohort of pCCA
patients in two tertiary referral centers.
Methods. Patients diagnosed with pCCA between 2002
and 2014 were included from two tertiary referral centers
in the Netherlands. The selection criteria used by the Mayo
Clinic were retrospectively applied to determine the pro-
portion of patients that would have been eligible for LT.
Results. A total of 732 consecutive patients with pCCA
were identified, of whom 24 (4%) had PSC-associated
pCCA. Overall, 154 patients had resectable disease on
imaging and 335 patients were ineligible for LT because of
lymph node or distant metastases. An age limit of 70 years
led to the exclusion of 50 patients who would otherwise be
eligible for LT. After applying the Mayo Clinic criteria,
only 34 patients (5%) were potentially eligible for LT.
Median survival from diagnosis for these 34 patients was
13 months (95% CI 3–23).
Conclusion. Only 5% of all patients presenting with
pCCA were potentially eligible for LT under the Mayo
criteria. Without transplantation, a median OS of about
1 year was observed.
Perihilar cholangiocarcinoma (pCCA) is the most
common malignancy of the biliary tract and arises from
biliary epithelial cells at the liver hilum.1,2 The annual
incidence in Western countries is about 1–2 per 100,000.3
The standard curative option for patients with pCCA is a
radical surgical resection which is associated with a median
overall survival (OS) of 40 months after resection and a
5-year survival of 30–50%.4,5 The majority of patients with
pCCA ([ 80%), however, are considered unresectable at
the time of presentation.6,7 The median survival of patients
with unresectable disease is only 6 months, which can be
prolonged to a median of 12 months by palliative
chemotherapy including gemcitabine and cisplatinum.6–8
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There are three main reasons for unresectability in
patients with pCCA: the disease is locally advanced,
metastatic disease is present, or patients are unfit for major
surgery. Locally advanced disease is defined as invasion of
surrounding organs or vasculature, or bilateral segmental
biliary involvement, making surgical resection with nega-
tive resection margins and adequate liver remnant
difficult.9 Previous studies have shown that surgical
resection with a positive resection margin does not improve
survival.3,10 Palliative resection in metastatic disease has
not shown any survival benefit.3,11 Finally, resection of
pCCA is high-risk surgical procedure with a postoperative
90-day mortality rate between 5 and 18% in Western ser-
ies,12–15 and as such the possible benefit does not outweigh
the risks in patients with advanced age, serious co-mor-
bidity, or frailty.16–18
The Mayo Clinic and several other centers in the United
States and Europe are currently treating a select subgroup
of patients with locally advanced pCCA with neoadjuvant
chemoradiation and liver transplantation (LT).19–21 In
patients treated according to this protocol, a 5-year survival
of 53%, slightly superior to the survival of patients after
surgery for resectable disease, could be achieved.19,20 Even
though these are excellent results, a pre-transplant dropout
of 30% was noted, despite strict inclusion criteria that
result in an extensive patient selection.22 These impressive
results raise the question as to whether LT is underutilized
for patients with pCCA. The first objective of this study
was to apply the Mayo selection criteria to a consecutive
cohort of pCCA patients to determine the eligibility rate for
the Mayo Clinic LT protocol. The second objective was to
compare outcomes of pCCA patients eligible for LT who
underwent best supportive care or palliative chemotherapy
with published outcomes of the Mayo LT protocol.
METHODS
Data Collection
All patients with presumed pCCA between 2002 and
2014 at Erasmus MC University Medical Center, Rotter-
dam, and the Amsterdam UMC, Academic Medical Center,
Amsterdam, the Netherlands, were identified by a sys-
tematic search in all medical records including: discharge
letters, minutes of multidisciplinary hepatopancreatobiliary
tumor board, radiology reports, operative reports, endo-
scopic reports, and pathology reports. Demographics (e.g.,
age and gender), clinical data [e.g., cholangitis, primary
sclerosing cholangitis, body mass index (BMI)], and lab-
oratory results [e.g., cancer antigen (CA) 19-9 levels] were
collected from medical records. The Institutional Review
Boards of both centers approved the study and the need for
individual informed consent was waived.
pCCA was defined as a mass or malignant-appearing
stricture at or near the biliary confluence, arising between
the origin of the cystic duct and the segmental bile ducts.2
If no histopathological evidence was obtained, the diag-
nosis was established by the multidisciplinary
hepatopancreatobiliary team based on clinical, radiologi-
cal, endoscopic and laboratory findings, and follow-up.23
All imaging [i.e., contrast-enhanced CT and/or dynamic
contrast-enhanced MRI or MRI with cholangiopancre-
atography (MRCP)] at the time of first presentation was
revised by experienced abdominal radiologists. The radi-
ologists were blinded for clinical information. Parameters
assessed on imaging were tumor size, Bismuth–Corlette
classification, lymph node and distant metastases, lobar
atrophy, and vascular involvement. Vascular involvement
was defined as apparent tumor contact of more than 180 to
the portal vein or hepatic artery.24
Intrahepatic and extrahepatic metastases were defined as
suspicion of metastases on imaging or found during staging
laparoscopy or exploratory laparotomy. Lymph node
metastases were classified in accordance with the AJCC
staging manual 7th edition; i.e., lymph nodes beyond the
hepatoduodenal ligament were classified as N2.
Eligibility for Liver Transplantation
The inclusion criteria composed by the Mayo Clinic
were applied to determine whether patients were eligible
for LT.20 The inclusion and exclusion criteria are sum-
marized in Table 1. The Mayo Clinic considered patients
with pCCA to be those with positive brush/biopsy or
malignant-appearing stricture or a mass on imaging with
CA 19-9[ 100 U/ml. Patients had to be deemed unre-
sectable (usually because of bilateral biliary involvement)
or diagnosed with advanced liver disease due to primary
sclerosing cholangitis (PSC). All patients should be medi-
cally fit for LT, interpreted here as WHO 0-2. As
neoadjuvant chemotherapy for pCCA is not routinely pre-
scribed for pCCA in the Netherlands, having received the
full regimen could not be assessed as a selection criterion.
Exclusion criteria of the Mayo protocol are intrahepatic,
extrahepatic, or lymph node metastases, and a history of
other malignancy within the last 5 years (excluding skin
and cervical cancers). Lymph node metastases and distant
metastases in our cohort were found at imaging, staging
laparoscopy, or exploratory laparotomy. Suspicion based
on imaging and suspicion/confirmation based on laparo-
scopy/laparotomy were pooled, as the clinical decision not
to perform resection was based on both imaging and sur-
gical exploration. Patients with tumor size over 3 cm of
radial (i.e., anterior–posterior) diameter were excluded, as
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well as patients who had undergone prior surgery for pCCA
or a transperitoneal biopsy of the tumor. Another exclusion
criterion for LT was uncontrollable infection despite drai-
nage procedures. Due to the retrospective nature of the
database we could not apply this criterion to our patients,
as clinical decisions pertaining to the uncontrollability of
the infection could not be univocally reconstructed.
Finally, patients aged older than 70 were not considered for
LT in the Mayo Clinic.
An LT protocol for pCCA patients has existed in the
Netherlands since 2011. The eligibility criteria are less
strict than the Mayo protocol and include irresectability, no
prior percutaneous drainage, tumor\ 3 cm, and absence of
lymph node and distant metastases.25 Patients do not
receive neoadjuvant chemoradiation.
Statistical Analyses
Statistical analyses were performed using SPSS version
24.0 (Armonk, NY). Overall survival (OS) was calculated
from the date of first presentation in the tertiary referral
center until death (event), last follow-up or loss to follow-
up (censoring). Continuous data were reported as median
with interquartile range (IQR). Categorical parameters
were reported as counts and percentages. Survival was
estimated using the Kaplan–Meier method and difference
across groups was tested using the log-rank test.
RESULTS
A total of 732 consecutive patients with pCCA were
identified (Table 2; Fig. 1). Of these patients, 462 (63%)
were male with a median age of 67 years. Most patients
(79%) had a good performance (WHO 0 or 1) status at the
time of diagnosis, even though 297 (43%) had cholangitis
before or at presentation in the referral center. Only 29
patients (4%) developed pCCA in the presence of PSC.
On imaging, patients had a tumor with a median radial
diameter of 2.7 cm (IQR 2.0–3.6; Table 3). Slightly more
than half of the patients had macrovascular involvement on
imaging. Suspected lymph node metastases were observed
in 35% of the patients and about 1/3 of patients had Bis-
muth class IV biliary involvement (i.e., isolation of the
second biliary radicle of both the left and right hepatic
duct). Laparoscopic staging was performed in 210 patients
(29%). Surgical exploration for resectable disease on
imaging was conducted in 345 patients (47%), of whom
154 patients (44%) underwent a curative-intent resection
(Fig. 1).
Eligibility for Liver Transplantation
After exclusion of the patients who underwent resection,
a further 80 patients were excluded based on WHO per-
formance status (67 had WHO 3 or 4 and 13 patients had an
unknown WHO status), leaving 498 patients that were
medically fit to undergo LT (Fig. 1). These patients had
similar baseline characteristics, yet worse tumor charac-
teristics than the patients who underwent resection
(Tables 1, 2). More patients in the unresected medically fit
group had a tumor larger than 3 cm (44% vs. 22%;
Table 3). The prevalence of invasion of portal vein (61%
vs. 39%) and/or hepatic artery (62% vs. 32%) invasion was
also higher in the medically fit group. Patients more fre-
quently had Bismuth class IV disease (38% vs. 23%), and
Blumgart T3 (53% vs. 23%). Finally, this group more often
TABLE 1 Eligibility criteria. Mayo protocol for liver transplantation for pCCA. Patients should fulfill all criteria
Inclusion criteria
1 Perihilar cholangiocarcinoma
2 Malignant appearing stricture on cholangiography; pathological confirmation; CA 19-9[ 100 U/ml; mass on imaging; polysomy on FISH
3 Unresectability or PSC diagnosis
4 Medical suitability for transplant
5 Completion of neoadjuvant chemotherapy
Exclusion criteria
1 Intrahepatic/extrahepatic/lymph node metastases on imaging, or at staging laparoscopy/exploratory laparotomy
2 Prior malignancy\ 5 years
3 Tumor[ 3 cm anterior–posterior
4 Prior abdominal radiotherapy/resection of cholangiocarcinoma
5 Uncontrolled infection
Age criterion
1 Age\ 70 years
CA 19-9 cancer antigen 19-9, FISH fluorescent in situ hybridization, PSC primary sclerosing cholangitis
Mayo Transplantation Eligibility
had suspected N2 nodes on imaging (19% vs. 9%) and
more confirmed nodal metastases during (exploratory)
surgery (14% vs. 0%). The same was the case for suspected
(13% vs. 3%) and confirmed (13% vs. 0%) metastatic
disease.
As part of the oncological exclusion criteria, 335
patients were excluded because of lymph node metastases
(n = 156) or distant metastases (n = 179; Fig. 1). Nodal or
distant metastases were diagnosed in 200 patients (59.7%)
based on radiological imaging or staging laparoscopy, and
in 135 (40.3%) patients during exploratory surgery. Six
patients had another malignancy\ 5 years before diagno-
sis, 1 patient had prostate cancer with palliative treatment,
and 1 patient had breast cancer with palliative treatment.
On imaging, 52 patients had a tumor larger than 3 cm, with
a median tumor size of 3.7 cm (IQR 3.5–4.5). No patient
received prior treatment for the tumor. Finally, 50 patients
were older than 70 years and were excluded based on the
age criterion only.
Possible Liver Transplantation Candidates
After applying the Mayo Clinic inclusion and exclusion
criteria, 34 patients were eligible out of a total cohort of
732 pCCA patients (5%; Fig. 1; Table 2). The median age
was 60 years (IQR 54–65; Table 2) and 22 patients were
male (65%). Two patients (6%) had PSC-associated pCCA.
In most patients, one or more traditional contraindications
for resection were present: main portal vein involvement
was present in 11 patients (32%), while common hepatic
artery involvement was observed in 3 patients (9%). Lobar
atrophy was present in 7 patients (21%). One in three
patients had Bismuth class IV disease (n = 11; 32%).
Twenty-one patients had Blumgart T3 disease (62%). Most
patients had surgically confirmed locally advanced disease:
staging laparoscopy was performed in 8 patients (24%);
while an exploratory laparotomy was performed in 19
patients (56%). Thirteen patients (38%) did not undergo
either staging laparoscopy or exploratory laparotomy.
Eleven eligible patients were diagnosed after 2011,
seven of whom underwent exploratory laparotomy. Two
patients underwent an LT, making the percentage of
patients who underwent LT in the 2011–2014 period 18%
(i.e., 2 out of 11). One patient who had PSC-related pCCA
received an LT in our cohort. Another patient was trans-
planted for Bismuth IV non-PSC related pCCA.
TABLE 2 Baseline characteristics
Characteristic Whole cohort
(n = 732)
Resected
(n = 154)
Medically fit
(n = 498)
Potential LT candidates
(n = 34)
Age at first presentation, years 67 (58–73) 65 (55–72) 67 (58–74) 60 (54–65)
70 years or older 296 (40) 49 (32) 209 (42) 0 (0)
Gender, male 462 (63) 98 (64) 311 (62) 22 (65)
Year of presentation
2001–2005 150 (21) 31 (20) 101 (20) 13 (38)
2006–2010 279 (38) 72 (47) 176 (35) 10 (29)
2011–2014 303 (41) 51 (33) 221 (44) 11 (32)
BMI, kg/m2 25 (22–27) 25 (22–27) 25 (22–27) 24 (22–28)
WHO performance status
0 332 (46) 90 (59) 242 (49) 20 (59)
1 235 (33) 44 (29) 191 (38) 13 (38)
2 81 (11) 16 (11) 0 (0) 1 (3)
3 60 (8) 3 (2) 0 (0) 0 (0)
4 10 (1) 0 (0) 0 (0) 0 (0)
CA 19.9 (U/ml)2 215 (64–1278) 104 (34–343) 292 (87–1793) 160 (26–299)
C 1000 U/ml 98 (27) 7 (9) 82 (32) 1 (5)
Primary sclerosing cholangitis 29 (4) 0 (0) 27 (5) 2 (6)
Biliary drainage 681 (94) 141 (92) 462 (94) 31 (91)
Cholangitis before or at presentation in referral
center
297 (43) 58 (38) 194 (42) 16 (52)
BMI body mass index, WHO World Health Organization, CA 19-9 cancer antigen 19-9
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Inclusion Criterion
1,2
3
4
1
2
3
4
1
Exclusion Criterion
Age Criterium
Perihilar
Cholangiocarcinoma
N=732
Unresectable or PSC
N=578
Medically Suitable
N=498
Potentially eligible
for LTX
N=34
Age > 70 years
N=50
–
Prior Treatment
N=0
Tumor > 3cm
N=52
Unknown N=8
Other malignancy
<5 years
N=8
Nodal metastases
N=156
Distant metastases
N=179
Unknown N=11
WHO 3/4 N=67
Unknown N=13
Resected (No PSC)
N=154
FIG. 1 Liver transplantation
eligibility. For nodal and distant
metastases, suspicion based on
imaging and
suspicion/confirmation based on
laparoscopy/laparotomy were
pooled
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Survival Estimates
The median follow-up of patients alive at last follow-up
was 4 years. During follow-up 661 patients (90.3%) died.
Median OS after diagnosis was 12 months (95% CI
11–14). For patients who underwent a resection, the med-
ian OS was 38 months (95% CI 29–48; Fig. 2), and 1-, 3-,
and 5-year survival rates were 82%, 54%, and 36%
respectively. Median OS for patients eligible for LT was
13 months (95% CI 3–23; p\ 0.001) without LT. The
survival at 6 months was comparable between patients
eligible for LT and resected patients (85% vs. 85%) and
superior to the 6-month survival of ineligible patients
(65%). The 1-, 3- and 5-year survival rates in the patients
eligible for LT were 56%, 18%, and 11%.
The patient who underwent LT for PSC-related pCCA in
our cohort is alive without recurrence at last follow-up,
4 years and 10 months after diagnosis. The patient with
non-PSC related pCCA died of disease recurrence after
2 years and 11 months.
DISCUSSION
This study on the applicability of the Mayo Clinic LT
protocol was conducted in a large consecutive cohort of
732 pCCA patients of whom only 34 (5%) would have
TABLE 3 Radiological staging and treatment
Characteristic Whole cohort (n = 732) Resected (n = 154) Medically fit (n = 498) Potential LT candidates (n = 34)
Tumor size, cm 2.7 (2.0–3.6) 2.1 (1.8–3.0) 2.9 (2.2–3.8) 2.3 (1.8–2.5)
Size[ 3 cm 253 (38) 33 (22) 195 (44) 0 (0)
Vascular involvement
PV involvement 376 (56) 58 (39) 277 (61) 17 (52)
Main/bilateral 133 (20) 6 (4) 103 (23) 11 (32)
HA involvement 366 (55) 47 (32) 279 (62) 15 (47)
Main/bilateral 90 (14) 3 (2) 74 (16) 3 (9)
Suspected lymph node involvement on imaging
N1 192 (27) 31 (20) 141 (29) 0 (0)
N2 120 (17) 13 (9) 89 (19) 0 (0)
Distant metastases on imaging 76 (11) 5 (3) 62 (13) 0 (0)
Lobar atrophy on imaging
None 514 (75) 107 (72) 348 (74) 27 (79)
Right 49 (7) 15 (10) 28 (6) 1 (3)
Left 127 (18) 27 (18) 94 (20) 6 (18)
Bismuth classification
I 37 (6) 12 (8) 21 (5) 1 (3)
II 75 (11) 13 (9) 49 (11) 8 (24)
IIIA 180 (27) 47 (31) 114 (25) 7 (21)
IIIB 136 (20) 35 (23) 99 (22) 7 (21)
IV 235 (35) 34 (23) 172 (38) 11 (32)
Blumgart classification
T1 204 (30) 69 (47) 117 (25) 9 (27)
T2 146 (22) 40 (27) 98 (21) 4 (12)
T3 326 (48) 39 (26) 245 (53) 21 (62)
Staging laparoscopy 210 (29) 83 (54) 118 (24) 8 (24)
Surgical exploration 345 (47) 154 (100) 178 (37) 19 (56)
Curative resection 160 (22) 154 (100) 6 (1) 2 (6)
Palliative surgery 13 (2) 0 (0) 11 (2) 1 (3)
LN metastases 115 (16) 0 (0) 70 (14) (0)
Distant metastases 71 (10) 0 (0) 65 (13) (0)
Systemic chemotherapy 56 (8) 5 (3) 49 (10) 2 (6)
PV portal vein, HA hepatic artery, LN lymph node
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been for LT. Most patients who were ineligible had poor
performance status, nodal or metastatic disease, tumor
size[ 3 cm, age[ 70 years, or a combination of these
factors. Approximately 20% of patients are currently
treated with curative resection. Only two of the eligible
patients underwent LT according to the Dutch protocol, out
of 11 patients diagnosed after its implementation in 2011.
The majority of patients eligible for LT underwent best
supportive care with a median OS of only 13 months and a
5-year OS of 11%, which is clearly inferior to OS reported
for LT by the Mayo protocol. In patients treated according
to this protocol, a 5-year OS of 53% for patients who
started with neoadjuvant chemoradiation, and 70–90%
5-year OS after LT was observed.19,20,26 The survival at
6 months was comparable between patients eligible for LT
and resected patients (85% vs. 85%), indicating that
neoadjuvant treatment may be feasible in these patients.
The prognosis of unresectable pCCA is poor.27,28 In our
study, even in the selected cohort of 34 patients that would
have been eligible for LT, median survival was only
slightly more than a year. In contrast, patients who
underwent resection had a median survival of more than
3 years. This is a significant difference between patients
who are, in oncological terms, not always very different.
Therefore, LT may provide a treatment option for patients
with locally advanced disease, who currently have limited
treatment options. Indeed, the only treatment option
available to these patients is systemic treatment with
gemcitabine and cisplatinum.8 With LT, large steps can be
made with regards to survival. A 2016 study based on the
European Liver Transplant registry reported on 105 unre-
sectable patients up until 2010. Of these patients, 6 (5.7%)
had confirmed PSC-related pCCA, while 16 underwent
neoadjuvant chemoradiation. After LT, a 5-year overall
survival of 32% was observed.29
A striking difference between the Mayo Clinic cohort
and our cohort is the number of patients diagnosed with
PSC, an important risk factor for pCCA.19 In their largest
study to date, 63% of patients had PSC in the Mayo Clinic
cohort. The rate of patients with PSC in the other centers
was also 63%.20 Even though epidemiological studies show
the rate of PSC in pCCA patients might be as high as 10%
in some regions, this is a large overrepresentation.30 In
contrast, in our cohort only 4% of the total patient popu-
lation was diagnosed with PSC. This rate was 6% in the
patients that would have been eligible for LT. Because
cancer surveillance of patients with PSC is advised, pCCA
is possibly diagnosed at an earlier stage.31 In addition,
patients with technically resectable disease and PSC were
also eligible for LT. This has likely resulted in overrepre-
sentation of PSC patients as well as a lower stage and better
OS. This is also demonstrated by the superior 5-year per
protocol recurrence-free survival of 72% in PSC-related
pCCA, compared with 51% in non-PSC-related pCCA
(p = 0.06) in the Mayo series.20 The difference in PSC rate
possibly also explains the younger age (51 years vs.
60 years) and consequently better physical condition of
patients in the Mayo Clinic cohort. More differences might
exist between incidental pCCA and PSC-associated pCCA
patients, in whom oncogenic mutations are sometimes
noted before clinical manifestations and who have an
aberrant DNA methylation profile.32–34 Clinical implica-
tions of these differences have yet to be elucidated.
In most countries performing LT, a shortage of donor
livers exists. This is illustrated by the Eurotransplant 2017
report, with 2548 patients on the waiting list in 2017, and
1674 patients transplanted.35 A possible solution for this
problem is living-donor liver transplantation (LDLT). After
the first successful LDLT was performed by Strong and
colleagues in Australia, there was an initial surge in LDLT
in most Western countries.36,37 In the following years,
however, most centers have abandoned the practice in both
Europe and the US, because of concerns of donor safety
and technical challenges.37 As LDLT increases the number
of available donor livers, it might enable transplantation in
patients with an expected 5-year survival that is lower than
typically accepted for LT, such as pCCA patients.37,38 The
29% rate of living donors in the Mayo Clinic cohort is
evidence that LDLT is already being successfully utilized
for pCCA.
The Mayo protocol age criterion is perhaps too strict and
resulted in the exclusion of 50 patients aged 70 years or
older, who met all other criteria. Parallel to the general
aging population in the west, the average age of donors and
recipients of LT is increasing.39,40 Both in the United
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States and Europe, the proportion of patients aged 65 years
and older has increased to 20% in recent years.39 During
the last decade, numerous studies reported the negative
impact of sarcopenia and frailty in LT candidates.41–43
Large-scale retrospective studies into the impact of clinical
aging markers on postoperative outcomes are already
available, and show clinically significant differences even
when age is taken into account.44–46 Rates of recipi-
ents[ 70 years old currently vary between 3% in the
United States and 1% in Europe.35,47 With strict selection,
the outcomes of elderly liver recipients is already similar to
younger patients.35,48,49 Despite current reluctance, the
increasingly advanced methods to determine physiological
condition as well as these promising LT results might be a
reason for more liberal interpretation of calendar age cri-
teria in the future.
In order to be included in the Mayo Clinic cohort, no
definite pathological confirmation was required. Instead, the
authors relied on a combination of clinical factors, including
positive biopsy, CA 19-9 and preoperative imaging, rea-
soning that pathological confirmation by transluminal brush
cytology or intraluminal biopsy is often not possible.50 In a
previous article by the same group, pCCA could be con-
firmed in half of the explants of patients in whom it could not
be demonstrated preoperatively.23 Due to the general scar-
city of donor livers and an increasing number patients in need
of an LT, this might raise concern.35,40 However, when
combining patients with preoperative pathologic proof,
pathologic proof at explant, and/or confirmed recurrence,
only 5% of patients remained in whom, despite strong clin-
ical suspicion, pCCA could not be pathologically
confirmed.20 Therefore, pathological proof of pCCA pre-
transplant may not be such a major clinical problem.
This study has a number of limitations inherent to its
retrospective nature. First, 13 of the 34 patients (38%) in
our cohort that fulfilled all Mayo protocol criteria did not
undergo either laparoscopy or laparotomy as is prescribed
in the Mayo protocol. This might have resulted in under-
staging, because lymph node or distant metastases were
only evaluated on imaging in these 13 patients. In addition,
it was not possible to define and exclude uncontrolled
infection. As we did not take this exclusion criterion into
account, the number of eligible patients might be even
fewer. Therefore, the actual percentage of eligible patients
may be lower than 5%. Finally, due to missing values, 32
patients (4%) were excluded that might have been eligible.
As these limitations have opposite effects, we believe our
final estimate of 5% for the percentage of patients pre-
senting with pCCA that were eligible for the Mayo LT
protocol to be reasonably accurate.
In conclusion, only about 5% of patients presenting with
pCCA in a tertiary European setting will be eligible for the
Mayo LT protocol. With LT, some of these patients will
have a 5-year OS of 53%, that is clearly superior to the
median OS of 1 year for patients eligible for LT who only
receive systemic chemotherapy or best supportive care.
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